SI-BONE, Inc. (SIBN): Price and Financial Metrics
SIBN Price/Volume Stats
Current price | $15.95 | 52-week high | $29.51 |
Prev. close | $16.04 | 52-week low | $15.57 |
Day low | $15.73 | Volume | 667,800 |
Day high | $16.03 | Avg. volume | 472,858 |
50-day MA | $19.22 | Dividend yield | N/A |
200-day MA | $21.15 | Market Cap | 654.99M |
SIBN Stock Price Chart Interactive Chart >
SIBN POWR Grades
- SIBN scores best on the Sentiment dimension, with a Sentiment rank ahead of 96.49% of US stocks.
- SIBN's strongest trending metric is Stability; it's been moving up over the last 26 weeks.
- SIBN's current lowest rank is in the Value metric (where it is better than 12.77% of US stocks).
SIBN Stock Summary
- With a price/sales ratio of 6.36, SI-BONE INC has a higher such ratio than 83.48% of stocks in our set.
- As for revenue growth, note that SIBN's revenue has grown 32.4% over the past 12 months; that beats the revenue growth of 85.7% of US companies in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SIBN comes in at -10.82% -- higher than that of just 20.73% of stocks in our set.
- Stocks that are quantitatively similar to SIBN, based on their financial statements, market capitalization, and price volatility, are ZOM, CDXC, PYCR, MLSS, and PMD.
- SIBN's SEC filings can be seen here. And to visit SI-BONE INC's official web site, go to si-bone.com.
SIBN Valuation Summary
- In comparison to the median Healthcare stock, SIBN's price/earnings ratio is 166.9% lower, now standing at -19.5.
- Over the past 63 months, SIBN's price/earnings ratio has gone up 4.9.
Below are key valuation metrics over time for SIBN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
SIBN | 2023-12-29 | 6.4 | 4.9 | -19.5 | -20.9 |
SIBN | 2023-12-28 | 6.6 | 5.0 | -19.9 | -21.3 |
SIBN | 2023-12-27 | 6.6 | 5.0 | -19.9 | -21.3 |
SIBN | 2023-12-26 | 6.5 | 5.0 | -19.9 | -21.2 |
SIBN | 2023-12-22 | 6.5 | 4.9 | -19.6 | -20.9 |
SIBN | 2023-12-21 | 6.5 | 4.9 | -19.6 | -21.0 |
SIBN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SIBN has a Quality Grade of C, ranking ahead of 32.78% of graded US stocks.
- SIBN's asset turnover comes in at 0.425 -- ranking 111th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows SIBN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.425 | 0.889 | -0.227 |
2021-03-31 | 0.409 | 0.881 | -0.230 |
2020-12-31 | 0.417 | 0.879 | -0.268 |
2020-09-30 | 0.475 | 0.878 | -0.305 |
2020-06-30 | 0.473 | 0.884 | -0.313 |
2020-03-31 | 0.519 | 0.896 | -0.281 |
SIBN Price Target
For more insight on analysts targets of SIBN, see our SIBN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $40.86 | Average Broker Recommendation | 1.36 (Strong Buy) |
SI-BONE, Inc. (SIBN) Company Bio
SI-BONE, Inc. engages in the development of invasive surgical implant system. Its product, iFuse, seeks to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded on April 2008 by Mark A. Reiley and Jeffrey W. Dunn in and is headquartered in San Jose, CA.
Latest SIBN News From Around the Web
Below are the latest news stories about SI-BONE INC that investors may wish to consider to help them evaluate SIBN as an investment opportunity.
Si-Bone (SIBN) Crossed Above the 50-Day Moving Average: What That Means for InvestorsShould investors be excited or worried when a stock crosses above the 50-Day simple moving average? |
Insider Sell: President, Commercial Ops Anthony Recupero Sells 8,457 Shares of SI-BONE Inc (SIBN)In a recent transaction on November 17, 2023, Anthony Recupero, President of Commercial Operations at SI-BONE Inc, sold 8,457 shares of the company's stock. |
SI-BONE To Present at Piper Sandler 35th Annual Healthcare Conference on November 28, 2023SANTA CLARA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Tuesday, November 28, 2023, at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time. Investors interested in listening to the conference call may do so b |
SI-BONE, Inc. (NASDAQ:SIBN) Q3 2023 Earnings Call TranscriptSI-BONE, Inc. (NASDAQ:SIBN) Q3 2023 Earnings Call Transcript November 6, 2023 Operator: Good afternoon and welcome to SI-BONE’s Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question and answer session towards the end of today’s call. As a reminder, this call is being […] |
Q3 2023 SI-BONE Inc Earnings CallQ3 2023 SI-BONE Inc Earnings Call |
SIBN Price Returns
1-mo | -23.76% |
3-mo | -20.17% |
6-mo | -27.07% |
1-year | -18.58% |
3-year | -52.85% |
5-year | -16.10% |
YTD | -24.01% |
2023 | 54.34% |
2022 | -38.77% |
2021 | -25.72% |
2020 | 39.07% |
2019 | 2.92% |
Continue Researching SIBN
Here are a few links from around the web to help you further your research on SI-BONE Inc's stock as an investment opportunity:SI-BONE Inc (SIBN) Stock Price | Nasdaq
SI-BONE Inc (SIBN) Stock Quote, History and News - Yahoo Finance
SI-BONE Inc (SIBN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...